Dipna Pharmachem Ltd. Q1 Revenue Rises 9.9%, Profit Falls 31%
Key highlights
- Dipna Pharmachem reported Q1 FY27 revenue from operations of Rs 20.33 crore, up 9.9% year-on-year.
- Q1 FY27 net profit fell 31.6% to Rs 0.39 crore from Rs 0.57 crore a year earlier.
- FY26 standalone net sales increased 3.33% to Rs 129.08 crore.
- FY26 net profit rose 170.3% to Rs 2.63 crore, while basic EPS increased to Rs 1.00.
powered by IRIS

Dipna Pharmachem Ltd. reported Q1 FY27 revenue from operations of Rs 20.33 crore, up 9.9% year-on-year, but net profit declined 31% to Rs 0.39 crore as profit before tax slipped and the company recorded a Rs 0.13 crore tax charge. The result follows a stronger FY26, when annual net profit rose 170.3% to Rs 2.63 crore.
Know Dipna Pharmachem inside out
Results, valuation, peers and who's buying, in one view.
What did Dipna Pharmachem report for Q1 FY27?
Dipna Pharmachem reported revenue from operations of Rs 20.33 crore for the quarter ended June 2026, compared with Rs 18.50 crore in the corresponding quarter a year earlier. Total income stood at Rs 23.79 crore. The sales increase indicates that the company began FY27 with higher business volume than in the same period of FY26.
However, the improvement in revenue did not translate into higher quarterly earnings. Profit before tax was Rs 0.52 crore, against Rs 0.57 crore a year earlier, a decline of about 8%. Net profit was Rs 0.39 crore, compared with Rs 0.57 crore in Q1 FY26. The year-earlier period had no comparable tax charge, while the latest quarter included tax of Rs 0.13 crore.
The Q1 result therefore shows a difference between sales growth and profit growth. Revenue expanded by 9.9%, but the lower pre-tax profit and tax expense reduced the bottom-line outcome. The reported Q1 earnings per share were Rs 0.15, versus Rs 0.24 a year earlier.
Why did quarterly profit fall despite higher sales?
Quarterly profit fell because pre-tax earnings were lower than a year earlier and a tax charge was recorded in the latest period. Dipna Pharmachem's profit before tax declined by Rs 0.05 crore year-on-year, while the Rs 0.13 crore tax expense further reduced the profit available to shareholders.
The supplied results context also attributes the pressure on earnings to higher finance costs and other costs. No detailed quarter-on-quarter cost breakdown has been provided in the available data, so the reported figures do not establish the individual contribution of each cost item. The key disclosed outcome is that revenue growth was not sufficient to offset the decline in pre-tax profitability.
For investors, the comparison is relevant because the company had delivered a sharp improvement in FY26 earnings. The Q1 FY27 profit of Rs 0.39 crore represents about 15% of FY26 net profit of Rs 2.63 crore. A single quarter does not determine the full-year result, but it establishes a lower profit base than the corresponding quarter last year.
How did Dipna Pharmachem perform in FY26?
Dipna Pharmachem ended FY26 with standalone net sales of Rs 129.08 crore, up 3.33% from Rs 124.92 crore in FY25. Operating profit before depreciation, interest and tax, excluding other income, rose 33.87% to Rs 5.02 crore from Rs 3.75 crore.
Interest expense declined 37.07% to Rs 1.46 crore in FY26 from Rs 2.32 crore in FY25. The company reported FY26 net profit of Rs 2.63 crore, up 170.3% from Rs 0.97 crore in the previous year. Basic earnings per share increased to Rs 1.00 from Rs 0.41.
The FY26 figures were approved by the board on July 2, 2026, alongside the company's first adoption of Ind AS. The available information states that no dividend was paid for FY26. Retained earnings therefore remained relevant to the company's reported financial position, which included total equity of about Rs 62.30 crore at March 2026.
Got a follow-up? Ask IRIS
What do the results mean for investors and operations?
The results mean that Dipna Pharmachem has reported higher quarterly sales but weaker profitability at the start of FY27. The distinction matters because FY26 revenue rose only 3.33%, while net profit increased much faster due to improved operating profit and lower interest expense. In Q1 FY27, the pattern has shifted, with sales expanding but profit before tax declining.
The company's reported annual revenue has also been volatile over a longer period. Revenue rose from Rs 100 crore in FY23 to Rs 164 crore in FY24, then declined to about Rs 125 crore in FY25 before recovering to Rs 129 crore in FY26. This history makes both sales consistency and cost control important measures in assessing subsequent results.
No dividend payout was reported for FY26, so shareholder returns disclosed in the provided information are linked primarily to earnings growth and changes in the company's financial position rather than cash distributions. The company has 262.89 lakh shares based on the supplied data, with paid-up share capital of Rs 26.29 crore.
When is Dipna Pharmachem's next earnings update?
Dipna Pharmachem's next stated earnings date is November 4, 2026. The company has quarterly reports available for June 2026 and September 2026 in its investor-document records, although the supplied data does not provide the financial figures for the September quarter.
The next update will provide investors with a further reported data point on whether revenue growth continues and whether profit before tax recovers from the Q1 level. It may also provide more detail on finance costs, tax expense and the relationship between total income and revenue from operations.
Conclusion
Dipna Pharmachem began FY27 with revenue from operations rising 9.9% to Rs 20.33 crore, but net profit fell 31.6% to Rs 0.39 crore. The result contrasts with FY26, when annual net profit rose 170.3% to Rs 2.63 crore on net sales of Rs 129.08 crore, supported by stronger operating profit and lower interest costs.
The next item to watch is the earnings update scheduled for November 4, 2026. That disclosure may clarify whether the Q1 gap between revenue growth and earnings was temporary and how tax, financing costs and operating profitability are progressing during FY27.


